| scholarly article | Q13442814 |
| P2093 | author name string | Wim C J Hop | |
| Elena N Levtchenko | |||
| Albert J van der Heijden | |||
| Joana E Kist-van Holthe | |||
| Jeroen Nauta | |||
| Eiske M Dorresteijn | |||
| P2860 | cites work | The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents | Q22305963 |
| Non-corticosteroid treatment for nephrotic syndrome in children | Q24246970 | ||
| Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. | Q36155384 | ||
| Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation | Q36566776 | ||
| A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children | Q43588188 | ||
| Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children | Q44398329 | ||
| Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome | Q44458286 | ||
| Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade | Q44481330 | ||
| Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome | Q44679612 | ||
| Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil | Q44749406 | ||
| Mycophenolate mofetil in children with multidrug-resistant nephrotic syndrome. | Q44764949 | ||
| The long-term course of cyclosporine-associated chronic nephropathy | Q44825054 | ||
| Switch from cyclosporine A to mycophenolate mofetil in nephrotic children | Q45272404 | ||
| Validation of a high-performance liquid chromatography method for the measurement of mycophenolic acid and its glucuronide metabolites in plasma | Q46313857 | ||
| Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration | Q46363542 | ||
| Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome | Q46488621 | ||
| Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. | Q46531570 | ||
| Estimation of the glomerular filtration rate in children: which algorithm should be used? | Q46678957 | ||
| Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome | Q46948718 | ||
| Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. | Q53360030 | ||
| Comparison between pre- and posttreatment renal biopsies in children receiving ciclosporine for idiopathic nephrosis. | Q54195680 | ||
| Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children | Q61590861 | ||
| Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children | Q67406480 | ||
| Safety and tolerability of cyclosporin A (Sandimmun) in idiopathic nephrotic syndrome. Collaborative Study Group of Sandimmun in Nephrotic Syndrome | Q67925915 | ||
| The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents | Q69035747 | ||
| Nephrotic syndrome: from toddlers to twenties | Q69367325 | ||
| Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children | Q70022886 | ||
| Renal effects of cyclosporin A in children treated for idiopathic nephrotic syndrome | Q70779851 | ||
| Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis | Q71305699 | ||
| Cyclosporine in the treatment of idiopathic nephrosis | Q72528912 | ||
| Effect of cyclosporin A on glomerular filtration rate in children with minimal change nephrotic syndrome | Q72771728 | ||
| Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy | Q73078589 | ||
| Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels | Q73114936 | ||
| Reproducible erythroid aplasia caused by mycophenolate mofetil | Q73639719 | ||
| Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. German Study Group on MMF Therapy in Pediatric Renal Transplant Recipients | Q74685641 | ||
| A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome | Q79331373 | ||
| P433 | issue | 11 | |
| P921 | main subject | cyclosporine | Q367700 |
| P304 | page(s) | 2013-2020 | |
| P577 | publication date | 2008-07-12 | |
| P1433 | published in | Pediatric Nephrology | Q15749796 |
| P1476 | title | Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome | |
| P478 | volume | 23 |
| Q35674857 | A series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood |
| Q33571864 | American Society of Nephrology quiz and questionnaire 2013: glomerulonephritis |
| Q43057633 | Analysis on the infection among patients with nephrotic syndromes and systemic vasculitis treated with mycophenolate mofetil |
| Q87402193 | Chapter 3: Steroid-sensitive nephrotic syndrome in children |
| Q83602331 | Clinical course and outcome of children with steroid-sensitive nephrotic syndrome |
| Q53625850 | Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. |
| Q53368686 | Clinical trials in minimal change disease. |
| Q38917805 | Comparison of second-line immunosuppressants for childhood refractory nephrotic syndrome: a systematic review and network meta-analysis |
| Q84459052 | Cyclophosphamide followed by mizoribine as maintenance therapy against refractory steroid-dependent nephrotic syndrome |
| Q92401273 | Efficacy and acceptability of immunosuppressive agents for pediatric frequently-relapsing and steroid-dependent nephrotic syndrome: A network meta-analysis of randomized controlled trials |
| Q47890306 | Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome |
| Q26745891 | History of Nephrotic Syndrome and Evolution of its Treatment |
| Q38917590 | How randomised trials have improved the care of children with kidney disease |
| Q57176874 | Idiopathic nephrotic syndrome in children |
| Q57477791 | Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolate mofetil prednisone: protocol for a randomised, controlled, multicentre trial (INTENT study) |
| Q39827261 | Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children |
| Q46912071 | Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome |
| Q84070917 | Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome |
| Q51529212 | Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. |
| Q56962909 | Mycophenolate mofetil for sustained remission in nephrotic syndrome |
| Q53086368 | Mycophenolate mofetil in steroid-dependent idiopathic nephrotic syndrome. |
| Q43232395 | Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome |
| Q37202763 | Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome |
| Q39573394 | Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome |
| Q35185376 | Nephrotic syndrome in children: from bench to treatment |
| Q40039238 | Nephrotic syndrome in infants and children: pathophysiology and management |
| Q38854254 | Nephrotoxicity in children with frequently relapsing nephrotic syndrome receiving long-term cyclosporine treatment |
| Q37828086 | New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome |
| Q24202861 | Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children |
| Q47267138 | Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil |
| Q36562448 | Paediatric use of mycophenolate mofetil |
| Q37709168 | Pharmacotherapeutic review and update of idiopathic nephrotic syndrome in children. |
| Q33764995 | Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. |
| Q86504669 | Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome |
| Q57945954 | References |
| Q37330330 | Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome |
| Q42723614 | Second-line options for refractory steroid-sensitive and -resistant nephrotic syndrome |
| Q38569641 | Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children. |
| Q54964024 | The Roche Total Mycophenolic Acid® assay: An application protocol for the ABX Pentra 400 analyzer and comparison with LC-MS in children with idiopathic nephrotic syndrome. |
| Q34618530 | The accumulated experience with the use of mycophenolate mofetil in primary glomerulonephritis |
| Q35226744 | Treatment of steroid and cyclosporine-resistant idiopathic nephrotic syndrome in children. |
| Q38050961 | Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. |
| Q24234648 | Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome |
| Q53170506 | [Comparison of therapeutic effects of prednisone combined with mycophenolate mofetil versus cyclosporin A in children with steroid-resistant nephrotic syndrome]. |
Search more.